Core Insights - The core viewpoint of the news is the performance and holdings of the Agricultural Bank of China Healthcare Stock Fund, which has shown significant growth in recent months and has a diversified portfolio in the healthcare sector [1]. Fund Performance - The latest net value of the Agricultural Bank of China Healthcare Stock Fund is 1.9462 yuan, reflecting a growth of 2.54% [1]. - The fund's return over the past month is 11.14%, ranking 101 out of 333 in its category [1]. - Over the last six months, the fund has achieved a return of 46.50%, ranking 10 out of 327 [1]. - Year-to-date, the fund has returned 42.73%, ranking 18 out of 327 [1]. Fund Holdings - The top ten holdings of the Agricultural Bank of China Healthcare Stock Fund account for a total of 51.10% of the portfolio, with the following key positions: - Heng Rui Medicine: 8.16% - Zai Lab: 7.99% - Xin Li Tai: 5.84% - Hotgen Biotech: 5.63% - Kelun Pharmaceutical: 5.02% - HAOYOBIO: 4.36% - BeiGene: 3.61% - Eucure Biopharma: 3.58% - Aosaikang: 3.52% - Bide Pharmaceutical: 3.39% [1]. Fund Background - The Agricultural Bank of China Healthcare Stock Fund was established on February 10, 2015, and as of June 30, 2025, it has a total scale of 1.441 billion yuan [1]. - The fund manager is Meng Yuan, who has a master's degree and has held various positions in the financial industry, including roles at Bank of China Fund Management and Agricultural Bank of China Asset Management [1].

Core Viewpoint - The company, Jiangsu Haobio Pharmaceutical Co., Ltd., is experiencing a decline in revenue and net profit, while its stock is trading at a significantly high price-to-earnings (PE) ratio compared to the industry average. Group 1: Company Performance - As of the latest report, the company achieved a revenue of 77.61 million yuan in Q1 2025, representing a year-on-year decrease of 9.33% [2] - The net profit for the same period was 1.64 million yuan, down 56.97% year-on-year, with a gross profit margin of 57.98% [2] - The company's stock closed at 116.9 yuan, with a PE ratio of 214.27, significantly higher than the industry average of 57.48 [1][3] Group 2: Industry Comparison - The average PE ratio for the medical device industry is 57.48, with a median of 40.95, placing Haobio at the 115th position among its peers [1][3] - The company holds 12 institutional investors, all of which are funds, with a total holding of 1.1392 million shares valued at 15.5 million yuan [1]

Company Overview - Jiangsu Haobio Pharmaceutical Co., Ltd. specializes in the research, production, and sales of in vitro diagnostic reagents, with key products including allergy reagents and autoimmune reagents [2] - The company has obtained 226 product registration certificates and holds 57 patents, recognized as a high-tech enterprise [2] Financial Performance - For Q1 2025, the company reported revenue of 77.61 million yuan, a year-on-year decrease of 9.33%, and a net profit of 1.64 million yuan, down 56.97% [2] - The gross profit margin stands at 57.98% [2] Market Position - As of August 5, the company's stock closed at 118.7 yuan, with a rolling PE ratio of 217.57 times, significantly higher than the industry average of 54.24 times and the median of 37.92 times [1][3] - The total market capitalization is 7.535 billion yuan [1] Institutional Holdings - By the end of Q1 2025, 12 institutions held shares in Haobio, with a total of 1.1392 million shares valued at 155 million yuan [1]

Core Viewpoint - Jiangsu Haooubo Biopharmaceutical Co., Ltd. announced that its wholly-owned subsidiary, Hunan Haooubo Biopharmaceutical Co., Ltd., has recently obtained three medical device registration certificates from the Hunan Provincial Drug Administration, enhancing its product offerings in the allergy testing market [1][2]. Group 1: Medical Device Registration - The company received three medical device registration certificates for allergy testing kits, which include: 1. A kit for quantitative detection of specific IgE antibodies for ragweed allergy [1]. 2. A kit for qualitative detection of specific IgE antibodies for food allergens [2]. 3. A kit for qualitative detection of specific IgE antibodies for inhalant allergens [2]. Group 2: Impact on the Company - The acquisition of these medical device registration certificates enriches the company's chemiluminescence platform testing menu, which is expected to enhance its market competitiveness and positively influence the sustainable development of the company and its subsidiaries [3].

Core Viewpoint - Jiangsu Haooubo Biopharmaceutical Co., Ltd. plans to sell land use rights and factory buildings to Suzhou Xinliancheng Software Co., Ltd. for a total price of 19.52 million yuan, aiming to optimize asset structure and maintain reasonable asset allocation [1][2][11] Transaction Overview - The transaction was approved at the 24th meeting of the third board of directors on August 1, 2025, and does not require shareholder approval [2][4] - The sale involves land use rights and factory buildings located at No. 218 Xinghu Street, Suzhou Industrial Park, with a total transfer price of 19.52 million yuan, including tax [2][3] - The transaction does not constitute a related party transaction or a major asset restructuring [1][4] Buyer Information - The buyer, Suzhou Xinliancheng Software Co., Ltd., was established on October 19, 2016, with a registered capital of 10 million yuan, primarily engaged in software development and sales [4][5] Asset Details - The asset being sold has a book value of 11,070,583.08 yuan as of June 30, 2025, with a historical cost of 17,339,100 yuan [6][5] - The asset is free from any encumbrances, litigation, or other restrictions on transfer [5][6] Valuation and Pricing - The asset was appraised at 19.01 million yuan as of June 19, 2025, resulting in a valuation increase of 71.75% compared to its book value [6][8] - The final transaction price of 19.52 million yuan was determined through negotiation, reflecting a fair and reasonable pricing principle [8][7] Payment and Delivery Terms - The payment structure includes a 95% payment within 30 working days after the contract becomes effective, with the remaining 5% due within 3 days after obtaining the property rights certificate [9][10] - The risk of loss or damage to the property will transfer to the buyer upon delivery or completion of the property rights registration [9][10] Impact on Company - The sale is intended to optimize the company's asset structure and will not affect its normal operations or harm the interests of shareholders, particularly minority shareholders [11]

Group 1 - The company, Haooubo (688656.SH), announced the sale of land use rights and factory buildings located at 218 Xinghu Street, Suzhou Industrial Park, Jiangsu Province to Chip Union Company as part of its overall strategic development plan [1] - The sale aims to further optimize the company's asset structure and maintain reasonable asset allocation [1] - The agreed transfer price for the assets, including tax, is 19.52 million yuan, with the final transaction price to be determined by the formal sale contract signed between the company and Chip Union [1]

Core Viewpoint - The company, Haooubo (688656.SH), is selling its land use rights and factory buildings located in Suzhou Industrial Park, Jiangsu Province, to Chip Union Company as part of its overall strategic development plan to optimize asset structure and maintain reasonable asset allocation [1] Group 1 - The asset being sold includes land use rights and factory buildings at a specific address in Suzhou [1] - The total consideration for the asset sale is 19.52 million yuan, which includes tax [1] - The final transaction price will be determined by the formal sale contract signed between the company and Chip Union [1]

浩欧博（SH 688656，收盘价：120.29元）8月4日晚间发布公告称，江苏浩欧博生物医药股份有限公司 全资子公司湖南浩欧博生物医药有限公司于近日获得湖南省药品监督管理局核准签发的3项医疗器械注 册证。包括"葎草（W22）过敏原特异性IgE抗体检测试剂盒"等产品。 2024年1至12月份，浩欧博的营业收入构成为：医疗器械占比97.39%，其他业务占比2.61%。 （文章来源：每日经济新闻） ...

证券代码：688656 证券简称：浩欧博 公告编号：2025-040 江苏浩欧博生物医药股份有限公司 关于出售土地使用权、厂房建筑物的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 交易简要内容：2025 年 8 月 1 日，江苏浩欧博生物医药股份有限公司（以下 简称"公司"）召开了第三届董事会第二十四次会议，审议通过了《关于公司拟 出售土地使用权、厂房建筑物的议案》，公司拟向苏州芯联成软件有限公司有限 公司（以下简称"芯联成公司"）出售公司拥有的不动产权证号为苏（2018）苏 州工业园区不动产权第 0000153 号坐落于江苏省苏州市苏州工业园区星湖街 218 号 17 幢（C6 栋）的土地使用权、厂房建筑物，经双方协商，本次转让价格预计 为 1,952.00 万元（含税）。 本次交易不构成关联交易。 本次交易不构成重大资产重组。 本次交易不存在为拟出表控股子公司提供担保、委托其理财，以及该拟出表 控股子公司占用公司资金的情形。 本次出售资产事项尚需交易双方根据协议完成款项支付、产权交割等程序， 存 ...

江苏浩欧博生物医药股份有限公司 关于自愿披露全资子公司获得医疗器械注册证的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 证券代码：688656 证券简称：浩欧博 公告编号：2025-041 上述医疗器械注册证的取得，进一步丰富了公司化学发光平台检测菜单，有 助于提升公司市场综合竞争力，对公司及子公司的可持续性发展将产生积极影响 和促进作用。 三、 风险提示 公司高度重视产品研发，并严格控制产品研发、制造及销售环节的质量及安 全。上述产品获证后的实际销售情况取决于未来市场拓展效果，公司目前尚无法 预测上述产品对公司未来业绩的影响。公司将及时根据后续进展履行信息披露义 务，敬请广大投资者谨慎决策，注意防范投资风险。 特此公告。 江苏浩欧博生物医药股份有限公司 董事会 2025 年 8 月 5 日 江苏浩欧博生物医药股份有限公司（以下简称"公司"）全资子公司湖南浩 欧博生物医药有限公司于近日获得湖南省药品监督管理局核准签发的 3 项医疗 器械注册证，现将有关情况公告如下： 序号 注册人 名称 产品名称 注 ...